|
Alliance Pharma PLC - Chippenham, England-based distributor of consumer healthcare brands and prescription medicines - Says see-through revenue in the first six months of 2023 is £82.4 million, up 1.1% from £81.6 million a year ago. ‘Whilst the first half had a mixed performance with regulatory issues resulting in some manufacturing delays in certain smaller products, revenue growth for the Kelo-Cote franchise and Nizoral was in line with the board’s expectations, and Amberen revenues returned to growth in [the second quarter] on a like-for-like basis,’ firm says. Free cash flow in the six months to June 30 doubles to £10.8 million from £5.1 million a year prior. Looking ahead, Alliance Pharma says expectation for full year operating performance is unchanged. Current stock price: 47.24 pence, up 3.7% on Tuesday 12-month change: down 59% Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
